A Multicenter Phase II Study on Atezolizumab plus Bevacizumab Combination Therapy in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh Classification B Cirrhosis: CHALLENGE Trial - Pu
2 hours ago
- #Atezolizumab-Bevacizumab
- #Child-Pugh B
- #Hepatocellular Carcinoma
- The CHALLENGE trial was a multicenter phase II study evaluating atezolizumab plus bevacizumab (atezo + bev) in patients with unresectable hepatocellular carcinoma (HCC) and Child-Pugh B cirrhosis.
- The study included 30 eligible patients with Child-Pugh scores of 7 or 8 who had not received prior systemic therapy.
- The serious adverse event (SAE) frequency was 23.3%, significantly below the threshold of 68.5%, indicating the regimen can be safely administered.
- Objective response rates were 40.0% by RECIST v1.1 and 46.7% by modified RECIST, showing demonstrable antitumor effects.
- Median progression-free survival was 240 days and overall survival was 470 days, with Child-Pugh scores remaining stable during treatment.
- The study concluded that atezo + bev is a promising option for this patient group, though additional studies are warranted.